220 related articles for article (PubMed ID: 17380203)
1. CD38 as a therapeutic target.
Stevenson GT
Mol Med; 2006; 12(11-12):345-6. PubMed ID: 17380203
[TBL] [Abstract][Full Text] [Related]
2. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2553. PubMed ID: 30524421
[TBL] [Abstract][Full Text] [Related]
3. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
[No Abstract] [Full Text] [Related]
4. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
[TBL] [Abstract][Full Text] [Related]
6. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.
Stevenson FK; Bell AJ; Cusack R; Hamblin TJ; Slade CJ; Spellerberg MB; Stevenson GT
Blood; 1991 Mar; 77(5):1071-9. PubMed ID: 1995092
[TBL] [Abstract][Full Text] [Related]
7. [CD38 antibodies in multiple myeloma].
Moreaux J
Med Sci (Paris); 2019 Dec; 35(12):1001-1004. PubMed ID: 31903907
[TBL] [Abstract][Full Text] [Related]
8. CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma.
Chen X; Wong OK; Reiman L; Sherbenou DW; Post L
Mol Cancer Ther; 2024 Feb; 23(2):127-138. PubMed ID: 37816503
[TBL] [Abstract][Full Text] [Related]
9. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
van de Donk NWCJ; Usmani SZ
Front Immunol; 2018; 9():2134. PubMed ID: 30294326
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.
Peng KW; Donovan KA; Schneider U; Cattaneo R; Lust JA; Russell SJ
Blood; 2003 Apr; 101(7):2557-62. PubMed ID: 12433686
[TBL] [Abstract][Full Text] [Related]
12. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
13. The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
Shallis RM; Terry CM; Lim SH
Cancer Immunol Immunother; 2017 Jun; 66(6):697-703. PubMed ID: 28341874
[TBL] [Abstract][Full Text] [Related]
14. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
An N; Hou YN; Zhang QX; Li T; Zhang QL; Fang C; Chen H; Lee HC; Zhao YJ; Du X
Mol Pharm; 2018 Oct; 15(10):4577-4588. PubMed ID: 30185037
[TBL] [Abstract][Full Text] [Related]
15. CD38 as an immunotherapeutic target in multiple myeloma.
Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
Sanchez L; Wang Y; Siegel DS; Wang ML
J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
[TBL] [Abstract][Full Text] [Related]
17. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
[TBL] [Abstract][Full Text] [Related]
18. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
Green DJ; O'Steen S; Lin Y; Comstock ML; Kenoyer AL; Hamlin DK; Wilbur DS; Fisher DR; Nartea M; Hylarides MD; Gopal AK; Gooley TA; Orozco JJ; Till BG; Orcutt KD; Wittrup KD; Press OW
Blood; 2018 Feb; 131(6):611-620. PubMed ID: 29158362
[TBL] [Abstract][Full Text] [Related]
19. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma.
Ellis JH; Barber KA; Tutt A; Hale C; Lewis AP; Glennie MJ; Stevenson GT; Crowe JS
J Immunol; 1995 Jul; 155(2):925-37. PubMed ID: 7608568
[TBL] [Abstract][Full Text] [Related]
20. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2559. PubMed ID: 30459772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]